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Abstract 
Background: Perivascular stromal cells (PSCs) are a recently identified cell type that comprises a small percentage of 
the platelet derived growth factor receptor-β+ cells within the CNS perivascular space. PSCs are activated following 
injury to the brain or spinal cord, expand in number and contribute to fibrotic scar formation within the injury site. 
Beyond fibrosis, their high density in the lesion core makes them a potential significant source of signals that act on 
neural cells adjacent to the lesion site.
Results: Our developmental analysis of PSCs, defined by expression of Collagen1a1 in the maturing brain, revealed 
that PSCs first appear postnatally and may originate from the meninges. PSCs express many of the same markers as 
meningeal fibroblasts, including expression of the retinoic acid (RA) synthesis proteins Raldh1 and Raldh2. Using a 
focal brain ischemia injury model to induce PSC activation and expansion, we show a substantial increase in Raldh1+/
Raldh2+ PSCs and Raldh1+ activated macrophages in the lesion core. We find that RA levels are significantly elevated 
in the ischemic hemisphere and induce signaling in astrocytes and neurons in the peri-infarct region.
Conclusions: This study highlights a dual role for activated, non-neural cells where PSCs deposit fibrotic ECM 
proteins and, along with macrophages, act as a potentially important source of RA, a potent signaling molecule that 
could influence recovery events in a neuroprotective fashion following brain injury.
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Background
Following CNS injury, the initial, local cellular response is 
protective, confining the injury and preventing extensive 
inflammation and neurodegeneration [7, 41], but large 
amounts of fibrosis and extracellular matrix (ECM) pro-
tein deposition can impede neuronal repair [8, 46]. Peri-
cyte-like cells termed perivascular stromal cells (PSCs) or 
type “A” pericytes have been identified as a major source 
of ECM proteins that generate the fibrotic scar, separate 
from the well-characterized astroglial scar, within the 
injured CNS tissue following both spinal cord and stroke 
injury [9, 11, 31, 48]. Beyond their role in fibrotic scar 
formation, however, PSCs in the lesion core are uniquely 
positioned to interact with a variety of resident (glia, neu-
rons, microglia) and infiltrating inflammatory cell types 
in the days and weeks post-injury.
Despite the profound response of PSCs to brain injury 
and their role in fibrotic scar formation, much remains 
unknown about this cell type. A few unique and defin-
ing characteristics of PSCs have been reported. These 
include (1) expression of platelet derived growth factor 
receptor-β (PDGFrβ), but not the pericyte marker desmin 
and (2) they are labeled in GLAST-CreErt [11] and Colla-
gen1a1-GFP (Col1a1-GFP) [48] transgenic mouse lines. It 
is not clear, however, if the cells labeled by the two trans-
genic mouse lines are the exact same cell population. That 
said, both lines label a subset of perivascular cells that are 
PDGFrβ+/desmin-negative and cells labeled by the two 
lines increase in number and fill the lesion core following 
spinal cord injury in a similar manner. In addition to line-
age ambiguity, developmental characterization of PSCs is 
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lacking and other, non-fibrosis functions for PSCs post-
injury have not been identified.
Activity of the Col1a1 promoter (Col1a1-GFP) has pre-
viously been shown to identify PSCs in the spinal cord 
[48]. Here we use protein expression of Col1a1 to identify 
PSCs and characterize the temporal and spatial distribu-
tion of Col1a1+ PSCs in the maturing brain. We observe 
that Col1a1+ PSCs are largely absent in the early postna-
tal brain, but increase in number over the first three post-
natal weeks. Initially, Col1a1+ cells are associated with 
vessels near the meningeal surface, but as their numbers 
increase so does their depth within brain regions. This 
information, along with the observation that Col1a1+ 
PSCs express many of the same markers as meningeal 
fibroblasts, suggests that Col1a1+ PSCs may originate 
from the meninges during postnatal brain develop-
ment. Meningeal fibroblasts express enzymes Raldh1 
and Raldh2 required for synthesis of retinoic acid (RA), 
a hormone with diverse functions in the CNS includ-
ing neurogenesis and cell survival. We find Col1a1+ 
PSCs in the un-injured brain express both Raldh1 and 
Raldh2. This sets up the possibility that expansion of 
PSCs capable of RA synthesis within a brain injury site 
creates a source of RA that can act on cells within and 
adjacent to the injury. We tested this idea using a focal 
brain ischemia model in mice (middle cerebral artery 
occlusion or MCAO) which has previously been shown 
to lead to a substantial increase in PSCs within the lesion 
site [9]. Analysis of Raldh1 and Raldh2 expressing cells at 
day 7 post-injury revealed that in addition to numerous 
Raldh1 and 2-expressing PSCs, Raldh1 was expressed by 
macrophages within the lesion core. Consistent with an 
increase in Raldh1 and Raldh2 expressing cells, RA levels 
were significantly elevated in the ischemic hemispheres 




Wild type [postnatal day 0 (P0), P7, P14, P21 and 6 week 
(wk)] C57Bl/6J, were used throughout this study unless 
otherwise noted. RA signaling was assessed using the 
retinoic acid response element or RARE transgenic 
mouse line (RARE-hsp68-LacZ) [43] purchased from 
Jackson Laboratories. Strict adherence to The Recom-
mended Guide for Care and Use of Laboratory Animals 
issued by the National Institutes of Health was per-
formed using animal protocols approved by the Institu-
tional Animal Care and Use Committee at The University 
of Colorado, Anschutz Medical Campus. All surgery 
was performed under anesthesia and suffering was 
minimized.
Tissue collection, immunohistochemistry and imaging
Animals were anesthetized with cryoanesthesia (P0) or 
60  mg/kg pentobarbital (≥P6) followed by transcardiac 
perfusion initially with PBS to clear red blood cells then 
4  % paraformaldehyde. Whole brain tissue was isolated 
and incubated in 4  % paraformaldehyde for 2  h, 20  % 
sucrose overnight and mounted in Tissue Tek for cryo-
secting. Sections at 12  µm were generated from fixed 
brain tissue and immunohistochemistry was performed 
as described in Zarbalis et  al. [53] using the follow-
ing antibodies: mouse anti-Col1a1 1:100 (Sigma); rabbit 
anti-Col1 1:100 (Abcam); rabbit anti-PDGFrβ 1:200 (Cell 
Signaling Technology); rat anti-PDGFrβ 1:200 (Novus 
Biologicals); rat anti-PDGFrα 1:200 (BD Bioscience); 
mouse anti-CoupTF2 1:300 (R&D); rabbit anti-Raldh1 
1:200 (Abcam); rabbit anti-Raldh2 1:400 (Sigma-Aldrich); 
mouse anti-CRABP1 1:100 (Abcam); rabbit anti-CRABP2 
1:100 (Proteintech); mouse CD68 1:500 (Dako); rab-
bit anti-β-galactosidase 1:500 (MP Biomed); chicken 
anti-β-galactosidase 1:500 (Abcam); mouse anti-NeuN 
1:500 (Millipore); rabbit anti-glial fibrillary acidic protein 
(GFAP) 1:500 (Sigma-Aldrich). Following incubation with 
primary antibodies, sections were incubated with appro-
priate Alexafluor-conjugated secondary antibodies (Inv-
itrogen) at 1:500, Alexafluor 633-conjugated isolectin-B4 
(Invitrogen) at 1:500 to label blood vessels and microglia 
[3], and DAPI (4′,6-diamidino-2-phenylindole) to label 
nuclei (Invitrogen). The immunostained tissue sections 
were imaged using confocal imaging (Zeiss 780 LSM).
Analysis of PSCs in postnatal and adult brain
Sagittal sections of P0, P7, P14, P21 and adult (6–8 week 
old mice) brains were produced as described above and 
immunostained with Col1a1, IB4 and DAPI. Tile scan, 
10× confocal images of the entire sagittal section of the 
brain at each time point were collected using a Zeiss 780 
LSM and associated Zen software. Brain regions were 
analyzed using the Zen Blue software for (1) the number 
of vessels (defined by labeling with IB4) with Col1a1+ 
cells (as defined by DAPI+ nuclei) per area of a brain 
region (area: cm2) and (2) average distance of vessels sur-
rounded by Col1a1+ cells from the pial surface (distance: 
µm). Regions measured at each time point were the cer-
ebral cortex, hippocampus, striatum, hypothalamus, 
thalamus, midbrain, hindbrain/cerebellum. We used the 
Allen Mouse Brain Atlas to define regional boundaries at 
each post-natal time point. For quantification of Raldh1 
and Raldh2 expressing cells in stroke brains at 7  days 
post-MCAO, 10, 10× fields per brain at the level of the 
ischemic core were analyzed for the number of Raldh1+ 
or Raldh2+ cells. Individual cells with positive staining 
were defined by presence of DAPI+ nuclei. The ischemic 
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core was defined by high density of IB4+ macrophages 
with amoeboid morphology. The number of positive 
cells was divided by the area analyzed (mm2) to gener-
ate a cell density for each field and averaged across all 
images to generate a mean for each brain. For compari-
son, we analyzed the non-ischemic cerebral cortex in the 
opposite hemisphere for Raldh1+/DAPI+ and Raldh2+/
DAPI+ cell density in the same manner. To analyze the 
number of GFAP+ astrocytes and NeuN+ neurons with 
RARE-LacZ transgene activity (defined by expression of 
β-galactosidase via antibody) in the non-ischemic cer-
ebral cortex and peri-infarct region, we collected 20×, 
4-by-4 tile scan confocal images of the peri-infarct region 
and a corresponding region in the cerebral cortex of the 
opposite hemisphere. For each brain, 4 tile scan images 
were collected in each hemisphere and analyzed for the 
number of β-gal+/GFAP+ and β-gal+/NeuN+ per area 
(mm2). The peri-infarct region was defined by activated, 
GFAP+ astrocytes. For each time point and type of 
analysis, a minimum of 3 animals were used for analysis 
(n ≥ 3).
Middle cerebral artery occlusion (MCAO)
MCAO animals were generated as described in Kel-
ley et  al. [20]. Briefly, adult male, wildtype C57Bl/6J or 
RARE-hsp26-LacZ/+ maintained on the ICR background 
(8–12  weeks old) mice were anesthetized and following 
baseline measurements of blood flow, unilateral MCAO 
was performed by inserting a 6.0 nylon monofilament 
into the internal carotid artery through a midline ventral 
neck incision. The filament was positioned for occlusion 
at 6 mm from the internal carotid/pterygopalatine artery 
bifurcation for 60  min. After the occlusion period ani-
mals were removed from anesthesia and no pain reliev-
ing drugs were administered to prevent confounding of 
outcomes. Brain tissue was collected 7 days post MCAO 
as described for histology or analysis of retinoid and RA 
levels.
RA quantification
Non-injury or MCAO brains were hemisected and the 
cortex/striatum from the right and left hemispheres were 
harvested in low light conditions to prevent RA degrada-
tion, frozen separately and kept at −80 °C until assayed. 
Tissue was homogenized and retinoids were extracted 
with a liquid–liquid extraction method for retinoids 
that has been described in detail previously [17]. RA 
was quantified by high performance liquid chromatog-
raphy (HPLC)-multistage tandem mass spectrometry 
using a Fast HPLC-multiple reaction monitoring cubed 
(LC-MRM3) method [14]. Retinol and total retinyl ester 
were quantified by high performance liquid chromatog-
raphy–ultraviolet detection (HPLC–UV) [16]. Results 
are given as mole retinoid per gram tissue and expressed 
as mean ± SEM with n = 2 for each control brain hem-
isphere (right and left) and n =  3 for each stroke brain 
hemisphere (right and left). Statistical significance was 
assessed using a two-tailed, unpaired Student’s t test 
(GraphPad).
Statistics
One-Way ANOVA and Student–Newman–Keuls post 
hoc analysis were used to assess statistically significant 
differences for PSC counts and distances. To address cor-
relation between cell counts and distance, Pearson Cor-
relation was performed. To detect statistically significant 
differences in mean values between two groups, Student 
t-tests were used. The standard error of the mean (SEM) 
is reported on all graphs.
Results
Temporal and spatial distribution of Col1a1+ PSCs in the 
early postnatal mouse brain
The Col1a1-GFP transgenic line has been used to identify 
a subset of perivascular cells that dramatically expand in 
number in response to a spinal cord injury [48] that have 
the same characteristics of PSCs described in stroke injury 
[9]. Therefore, Col1a1 expression can be used to identify 
PSCs in the uninjured brain. Using an antibody to Col1a1, 
we observe Col1a1+ cells in the meninges surrounding the 
mouse brain (Fig. 1A, B, carets). Within the brain paren-
chyma at P7 and P21, we observe some large diameter 
vessels with Col1a1+ cells surrounding them (Fig. 1A, B, 
arrows; arrows in A′, B′ insets indicate Col1a1+/DAPI+ 
cells surrounding IB4+ blood vessel). We next character-
ized the spatial and temporal distribution of vessels with 
associated Col1a1+ PSCs from P0 to adulthood. We did 
not observe Col1a1+ PSCs at E16.5 in the developing 
embryonic brain (data not shown). At P0, vessels with 
Col1a1+ cells were observed in the hippocampus, but very 
infrequently in all other brain regions analyzed (cortex, 
striatum, hypothalamus, thalamus, midbrain and hind-
brain/cerebellum, Fig. 1C). PSC numbers in the hippocam-
pus were reduced to the infrequent levels found in other 
brain regions at 1 week (P7, 1C). As the postnatal vascu-
lature and neural tissue continued to mature, there was 
an increase in Col1a1+ cell-associated vessels at 2 weeks 
in all brain regions (P14, Fig. 1C) followed by a fairly sta-
ble PSC cell population during the remainder of postnatal 
development and into adulthood (P21 and Adult, Fig. 1C). 
The increase in number of vessels with Col1a1+ PSCs was 
significant for the cortex and striatum from P0 to adult 
(Fig. 1C, *p < 0.05) and for the hippocampus and hypothal-
amus from P14 (Fig. 1C, #p < 0.05).
The majority of vessels with Col1a1+ cells at P7 were 
located near the meningeal surface of the brain (Fig. 1A, 
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arrows), but as the Col1a1+ cell population expanded 
there appeared to be a corresponding increase in dis-
tance from the meningeal surface (Fig.  1B, arrows). To 
quantify this we measured the distance of Col1a1+ 
PSC-associated vessels from the meningeal surface in all 
brain regions at P0, P7, P14, P21 and 6 weeks (Fig. 1D). 
We observed a relationship between developmental time 
progression and PSC distance from the pial surface in 
that the average distance from the pial surface increased 
over time in all brain regions (Fig. 1D). The correlation of 
cell number and distance from the pial surface was sta-
tistically significant for four of the seven brain regions 
scored (Fig.  1E). An increase in Col1a1+ PSC distance 
from the pial surface might be the result of increasing 
CNS tissue around the PSCs due to brain growth or, pos-
sibly, Col1a1+ cells originate in the meninges and “enter” 
the perivascular space via arterioles and venules that pen-
etrate the surface of the brain from the meningeal space. 
Consistent with this, Col1a1-GFP+ PSCs are associated 
with large diameter arterioles and venules, structures 
which are physically linked to the meningeal surface, 
but not small diameter capillaries [48]. This analysis also 
reveals new distinctions between pericytes and vascular 
smooth muscle cells (vSMCs) and Col1a1+ PSCs in that 
the postnatal spatial and temporal expansion of Col1a1+ 
cells contrasts with that of pericytes/vSMCs that undergo 
expansion and spatial distribution during prenatal neuro-
vascular development [2].
PSCs dynamically express both pericyte and meningeal cell 
markers
The positional analysis of Col1a1+ cell distribution sug-
gested that PSCs may originate from the meninges, 
thus we examined expression of meningeal cell markers 
within this population at P0 when PSCs are first observed 
in the mouse brain and in PSCs in the more mature brain 
at P21. We also examined expression of these markers in 
“activated” PSCs at 7 days post ischemic injury induced 
by 60 min MCAO.
PSCs co-express the population defining marker 
Col1a1 and PDGFrβ at both P0 (Fig.  2A, arrows), P21 
(Fig. 2B, arrows) and in the lesion core (Fig. 2C, arrows). 
Transcription factor CoupTF2 (Fig.  2D–F, nuclear) was 
expressed by the Col1a1+ meninges (Fig. 2D, carets) and 
by Col1a1+ PSCs at P0 (Fig.  2D, arrows), P21 (Fig.  2E, 
arrows) and in the stroke lesion by PDGFrβ+ PSCs 
(Fig.  2F, arrows) but not by Ib4+ macrophages (Fig.  2F, 
carets). We assayed for PDGFrα expression, previously 
shown to be expressed by inactive and active PSCs [9, 
11, 48], and found that Col1a1+ cells had weak PDGFrα 
expression at P0 (Fig.  2G, open-arrows), but it was 
strongly expressed at P21 and in lesion PSCs (Fig.  2H, 
I, arrows). PDGFrα expression is noteworthy because 
this receptor is also expressed by some meningeal fibro-
blasts (see Fig. 2G, H, carets), again pointing to a possible 
meningeal origin of PSCs.
PSCs express RA synthesis proteins and, along with 
macrophages, are a source of lesion‑derived RA
RA is a hormone with a variety of functions in the devel-
oping and adult brain [30]. Subsets of meningeal fibro-
blasts are one source of RA for the brain as they express 
enzymes required for RA synthesis [26, 45]. Our evi-
dence points to a possible meningeal origin for Col1a1+ 
PSCs, thus we looked at expression of RA synthesis 
enzymes Raldh1 and Raldh2 in Col1a1+ PSCs during 
postnatal development and in the 7  day post MCAO 
ischemic core. Raldh1 was expressed by some neurons 
in the postnatal brain as reported (Fig. 3A, arrows) [50] 
and by some Col1a1+ meningeal cells (Fig.  3A, carets) 
but not by Col1a1+ PSCs at P0 (Fig.  3A, open-arrows). 
At P21, however, we observed Raldh1 expression in 
Col1a1+ PSCs (Fig.  3B, arrows). Within the ischemic 
core, CoupTF2+ PSCs expressed Raldh1+ however 
we observed CoupTF2+ PSCs that did not express 
Raldh1 (Fig.  2C, arrows, open arrows respectively). We 
observed that IB4+ cells with ameboid morphology, 
typical of macrophages/microglia that are present in 
large numbers in the lesion core at this time point [12, 
47, 49], also expressed Raldh1 (Fig.  3C, carets). Raldh2, 
strongly expressed by the meninges, was also expressed 
by Col1a1+ PSCs at both P0 and P21, albeit very weakly 
(See figure on previous page.) 
Fig. 1 PSCs appear postnatally and increase in abundance and distance from meninges between P0 and adulthood. A, B Sagittal sections of P7 
and P21 brain depicting Collagen-1a1 (Col1a1, green) PSCs (arrows) in the midbrain and in the meninges (carets). A′, B′ Higher magnification insets 
of large diameter, IB4+ vessels (caret indicates DAPI+ nuclei in the inner endothelium of the vessel) with Col1a1+ PSCs surrounding them (arrows). 
Open-arrow in B′ indicates small diameter IB4+ vessel, likely a capillary. C Graph depicting analysis of density of blood vessels with Col1a1+ PSCs 
for each brain area (cortex, hippocampus, striatum, hypothalamus, thalamus, midbrain and hindbrain/cerebellum) in P0, P7, P14, P21 and adult 
brain. Asterisks (*) mark significant differences between P0 and adult and # symbols mark significant differences between P7 and adult. D Graph 
depicting scoring for the average distance from the pial surface of Col1a1+ PSC associated vessels per brain region (cortex, hippocampus, striatum, 
hypothalamus, thalamus, midbrain and hindbrain/cerebellum). Significant differences between P0 and adult are marked (*). E Table of significant 
Pearson Correlation Coefficients (r) and associated p values (p) for PSC cell count and distance measurements shown in C and D. In C and D, 3 
animals were scored at each time point with standard error bars. Scale bars 2 mm (A, B) and 50 µm (A′, B′)
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at P0 (Fig. 3D, E, open-arrows and arrows mark PSCs and 
carets indicate meninges). Many, but not all, CoupTF2+ 
PSCs in the lesion core were also Raldh2+ (Fig.  3F, 
arrows mark some Raldh2+/CoupTF2+ cells and open-
arrows mark the CoupTF1+/Raldh2-negative cells). We 
did not assay for Raldh3 expression as it is not reported 
to be expressed by the meninges [40].
Cellular Retinoic Acid Binding Proteins-1 and 2 
(CRABP1 and CRABP2) play a key part in RA signal-
ing within a cell in that they bind RA and shuttle it to 
its nuclear hormone receptors [39]. CRAPB1 was not 
extensively expressed by Col1a1+ meninges or PSCs 
at P0 (Fig.  3G, carets and open-arrows respectively) 
though we did observe CRABP1 in Col1a1+ PSCs at 
P21 (Fig. 3H, arrows). CRABP1 was broadly expressed in 
the lesion core, co-localizing with PDGFrα+ PSCs and 
other, unidentified cell types (Fig. 3I, arrows and carets, 
respectively). CRABP2 was expressed in the meninges 
(Fig.  3J, K, carets) at P0 and P21 but not in PDGFrα+ 
PSCs (Fig. 3J, K, open-arrows). In the lesion, a subset of 
PDGFrα+ PSCs co-expressed CRABP2 (Fig.  3L, arrows 
indicate PDGFrα+/CRABP2+ PSCs and open-arrows 
indicate PDGFrα+/CRABP2-negative PSCs).
Expression of RA synthesis enzymes (Raldh1 and 
Raldh2) indicates that cells in the ischemic lesion are a 
source of RA. We characterized this further by (1) co-
labeling sections from ischemic brains (60  min MCAO, 
7 days post-injury) with antibodies to Raldh1 and Raldh2 
(Fig.  4A–C) and analyzing the density of Raldh1+ and 
Raldh2+ cells in the non-ischemic hemisphere ver-
sus the lesion core (Fig.  4E, F) and (2) quantifying RA 
levels in uninjured, non-ischemic and ischemic hemi-
sphere at 7 days post 60 min MCAO (Fig. 4G). In non-
ischemic cerebral cortex, Raldh1/Raldh2 double positive 
Fig. 2 Expression of perictye and meningeal cell markers changes 
over maturation and post-injury activation of PSCs. Confocal images 
on sections from hippocampus (P0), thalamus or midbrain (P21) 
and cerebral cortex or striatum (MCAO) with antibodies that label 
pericytes and/or meningeal cells to characterize Col1a1+ PSC marker 
expression. Col1a1+ PSCs (green, A–C) express PDGFrβ (red, A–C) 
at P0 and P21 and in the post-MCAO lesion (arrows, A–C). At P0 and 
P21, PDGFrβ is also expressed by perivascular pericytes that do not 
have Col1a1 expression (carets, A, B). CoupTF2 (red, D–F) is expressed 
by Col1a1+ (green, D, E) PSCs surrounding IB4+ blood vessels at P0 
and P21 (arrows, D, E) and by PDGFβ+ PSCs (green, F) in the stroke 
lesion (arrows, F). Carets in D indicate CoupTF2 +/Col1a1+ cells in 
the meninges. IB4 in F also labels macrophages (blue, caret). PDGFrα 
is expressed in the meninges (red, carets, G, H), is weakly expressed 
by Col1+ PSCs at P0 (green, open-arrows, G) but is strongly expressed 
by these cells at P21 (arrows, H) and in the stroke lesion (arrows, I). IB4 
(blue) labels blood vessels and microglia/macrophages in A, D–H and 
DAPI (blue) marks nuclei in I. Scale bars 100 μm
▸
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PSCs were occasionally found in the perivascular space 
(Fig. 4A, carets). Within the ischemic core at 7 days post 
60  min MCAO, the number of Raldh1+ and Raldh2+ 
cells was dramatically increased (Fig. 4B). Some Raldh1+ 
cells co-localized with Raldh2 (Fig.  4C, arrows) and 
these likely represent activated PSCs in the lesion core 
that express both Raldhs. Other Raldh1+ cells did not 
co-localize with Raldh2 and, as shown in Fig.  3C, these 
Fig. 3 PSCs express RA pathway proteins. RA biosynthesis protein Raldh1 (red) is not expressed by Col1a1+ PSCs at P0 (green, open-arrows in A) but 
is expressed by some cells in the meninges (carets in A) and some neurons in the brain (arrows in A). At P21, Raldh1 (red, B) is expressed by Col1a1+ 
PSCs (green, B) surrounding blood vessels (arrows in B). In the stroke lesion, Raldh1 (red, C) is expressed in CoupTF2+ PSCs (green, arrows in C) and 
IB4+ macrophages (magenta, carets in C). Raldh2 (red, D, E) is expressed by Col1a1+ meningeal cells (green; carets in D, E), is only very weakly 
expressed by Col1a1+ PSCs surrounding IB4+ vessels at P0 (open-arrows, D), but Raldh2 signal is strong in Col1a1+ PSCs at P21 (arrows in E). 
Following stroke, Raldh2 (red, F) is expressed by CoupTF2+ PSCs (green, arrows in F). Some CoupTF2+ PSCs in the lesion do not express Raldh1 or 
Raldh2 (open-arrows in C, F). CRABP1 (red, G) is not expressed by Col1a1+ (green, G) meninges or PSCs at P0 (carets and open-arrows, respectively in 
G) though is expressed by Col1a1+ PSCs (green, H) surrounding IB4+ vessels at P21 (arrows in H). PDGFrα+ PSCs (red, I) in the stroke lesion express 
CRABP1 (green, arrows in I) though there are other CRABP1-expressing cells in the lesion (caret in I). CRABP2 (green, J, K) is expressed by PDGFrα 
meninges (red, carets in J, K) but not by PDGFrα+ PSCs (red open-arrows in J, K) at P0 or P21. CRABP2 (green, L) is expressed by some PDGFrα+ 
PSCs (red, arrows in L) in the stroke lesion. Open-arrows in L indicate PDGFrα+/CRABP2-negative cells. IB4 labels blood vessels and microglia/mac-
rophages in A, C, D, G, H, J and L; DAPI (blue) marks nuclei in B, C, E, F, I, and K. Scale bars 100 μm
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are macrophages. We further confirmed Raldh1 expres-
sion in macrophages by showing that Raldh1+ cells 
with ameboid morphology express the macrophage 
marker CD68 (Fig.  4D, carets) [36]. Raldh1+ (Fig.  4E) 
and Raldh2+ (Fig.  4F) cell density was significantly 
increased in the lesion core as compared to the con-
tralateral, non-ischemic cerebral cortex (p  <  0.05). We 
next tested whether the ischemia-induced increases in 
Raldh expressing PSCs and macrophages elevated lev-
els of RA in the ischemic hemisphere. RA levels were 
not significantly different between hemispheres from a 
non-injured brain and the non-injured left hemisphere 
(Fig. 4G) whereas the ischemic right hemisphere had sig-
nificantly elevated levels of RA (Fig. 4E) (p < 0.05). Addi-
tionally, retinol (vitamin A, a precursor to RA) as well as 
total RE (a storage form of vitamin A) were unchanged 
(data not shown), further supporting a change in produc-
tion of RA due to elevated number of Raldh+ cells in the 
lesion capable of synthesizing RA rather than an increase 
in available vitamin A. Collectively this data suggests 
that focal ischemia leads to elevated RA levels through 
injury-induced expansion of RA-synthesizing PSCs and 
macrophages.
To test whether elevated RA levels in the stroke hemi-
sphere activate RA signaling following stroke, we used 
the RA activity reporter mouse line RARE-hsp68-LacZ 
[43] to look for sites of active RA signaling at 7 days post 
60  min MCAO. Using an antibody to β-galactosidase 
(β-gal) to detect activation of the RARE-LacZ reporter 
gene, we observed expression of the reporter in the hip-
pocampus in both hemispheres (Fig.  5A; Hp) as has 
been described previously [10]. In the lesion hemisphere 
there was elevated reporter activity in the peri-infarct 
region (Fig.  5A–A″, infarct region outlined by dotted 
lines in 5A). Robust transgene activation was specific to 
the ischemic hemisphere as only low levels of transgene 
activity were observed in the contralateral hemisphere 
(Fig. 5A). To identify which cell types had RARE-hsp68-
LacZ transgene activity following injury, we assayed for 
specific cell markers within the cerebral cortex. In the 
non-injury hemisphere, neuronal marker NeuN co-
localized with some weakly positive β-gal expressing cells 
(Fig. 5B, carets), but we did not observe overlap between 
β-gal and the astrocyte marker GFAP (Fig.  5C). In the 
peri-infarct areas in the ischemic hemisphere, strongly 
labeled β-galactosidase+ cells co-localized with both 
NeuN (Fig. 5D, carets) and with astrocyte marker GFAP 
(Fig. 5E, carets). Consistent with analysis of RA levels, the 
number of NeuN+/β-gal+ (Fig. 5F) and GFAP+/β-gal+ 
(Fig. 5G) was significantly increased in peri-infarct region 
as compared to a similar region in the non-ischemic 
hemisphere (p  <  0.05). We used PDGFrα (Fig.  5H) and 
PDGFrβ (Fig. 5I) to look for RARE-hsp68-LacZ transgene 
activity PSCs in the non-lesion and lesion tissue, respec-
tively. Cells in the granule cell layer of the hippocampal 
dentate gyrus had transgene activity however PDGFrα+ 
PSCs did not co-localize with β-galactosidase (Fig.  5H, 
arrows). In the lesion core, PDGFrβ+ PSCs did not have 
overlapping β-gal expression (Fig.  5I, carets) but some 
had closely adjacent expression that appeared to be pro-
cesses (Fig. 5I, I′ open-arrows) possibly β-galactosidase+ 
astrocyte or neuronal processes as these cells were pre-
sent in the same area (Fig. 5I, arrows). Collectively these 
data show that neurons and astrocytes in the peri-infarct 
region are responding to RA synthesized by macrophages 
and PSCs within the lesion core.
Discussion
PSCs, aka Type “A” pericytes, represent a subset of 
PDGFrβ-expressing perivascular cells that are activated 
in the days following a CNS injury, expand in number 
and contribute significantly to fibrotic scar deposition [9, 
11, 31, 48]. The Col1a1-GFP mouse line labels a subset 
of perivascular cells that fit the primary characteristics 
of a PSC, most notable of which is expansion and ECM 
protein deposition following CNS injury. In this study, 
we first use the unique expression of Col1a1 by PSCs to 
delineate this population from pericytes and vSMCs in 
the perivascular space and gain knowledge about this cell 
type during CNS development. This analysis led to the 
observation that PSCs, like meningeal fibroblasts, express 
RA synthesis enzymes Raldh1 and Raldh2. We show that 
following a focal ischemic injury, increased numbers of 
Raldh-expressing PSCs and macrophages elevates RA 
levels that activates RA signaling in peri-infarct neurons 
and astrocytes. These findings support a novel function 
for PSCs and macrophages within the infarct core and 
raise new questions regarding the role of endogenous RA 
synthesis and signaling following focal brain ischemia.
Our observation that an expanded population of PSCs 
are, along with macrophages, a source of RA follow-
ing brain injury resulted from our interest in identify-
ing when and from where Col1a1+ PSCs originate. We 
find that Col1a1+ PSCs are only found in the postnatal 
brain and we have evidence that they may originate from 
the meninges. The latter is based on shared expression 
of meningeal fibroblast markers (e.g. Col1a1, PDGFrα, 
Raldh2, CoupTF2 and PDGFrβ) and the expanding dis-
tance of PSCs from the meningeal surface during postna-
tal development. Postnatal appearance of Col1a1+ PSCs 
contrasts with pericytes and vSMCs that enter the CNS 
along with blood vessels during prenatal CNS angiogen-
esis [2] and is another characteristic defining this unique 
perivascular population. It is also consistent with reports 
that there is almost no fibrotic scar deposition in the 
lesion site at P7 following experimental brain injury in 
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Fig. 4 Elevated RA synthesis and signaling in the ischemic hemisphere. Compared to the uninjured hemisphere (A), the number of cells express-
ing RA synthesizing enzymes Raldh1 (red) and Raldh2 (green) increases dramatically 7 days following 60 min MCAO (B). Carets in A and A’  insets 
mark Raldh1+/Raldh2+ PSCs around vessels in non-ischemic cortex. Arrows in C depict Raldh1+/Raldh2+ PSCs in the lesion. Carets in D indicate 
CD68+/IB4+ macrophages (green/magenta) express Raldh1 (red) in the lesion core. Graphs depicting quantification of cells expressing Raldh1 
(E) and Raldh2 (F) in injured and un-injured hemispheres. Fast LC-MRM3 quantification of RA (G) from left and right hemispheres of uninjured and 
60 min MCAO (right hemisphere) animals at 7 days post-injury. A minimum of 3 separate animals were analyzed (n ≥ 3) and error bars represent 
SEM. Asterisks indicate statistically significant difference (p < 0.05) from uninjured/non-ischemic hemisphere to ischemic hemisphere. DAPI marks 
nuclei in blue. Scale bars 20 µm (C), 50 µm (A′–A‴), and 100 μm (A, B, D)
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Fig. 5 Assessment of in vivo RA signaling activity. Spatial RA activity assayed using RARE-hsp68-LacZ mouse 7 days post 60 min MCAO injury. 
Confocal, tile-scan image of β-galactosidase immunolabeling (β-gal, green, A) with IB4 (magenta, A) at the level of the lesion (outlined with dashed 
line). A′ and A″ indicate magnified images in A. Tile stitched confocal images of RA activity in non-ischemic hemispheres (β-gal, green, B, C) and 
ischemic (β-gal, green, D–E) with markers for neurons (NeuN, red, carets, B, D), astrocytes (GFAP, red, carets, C, E). Insets are magnified areas with 
dotted lines in D and E. Graphs depict quantification of NeuN+/β-gal+ neurons (F) and GFAP+/β-gal+ astrocytes (G) from non-ischemic and 
ischemic hemispheres 7 days following a 60 min MCAO (n ≥ 3 and bars represent SEM). Asterisks indicate statistically significant difference (p < 0.05) 
from uninjured/non-ischemic hemisphere and the ischemic hemisphere. PDGFrα + PSCs (red) in the non-ischemic cortex did not co-localize with 
β-gal (arrows, H) though β-gal+ cells are present in the granule cell layer of the dentate gyrus (DG) (carets, H). β-gal+ processes (green, I) appear 
to contact PDGFrβ+ PSCs (red) in the lesion core (open-arrows in I and I′) but PDGFrβ+ PSCs do not appear to co-label with β-gal (caret, I). β-gal+/
PDGFrβ-negative cell bodies are adjacent to PDGFrβ+ PSCs (arrows, I). DAPI marks nuclei in blue. Scale bars 2 mm (A), 200 μm (B–E, I), 100 µm (H, I′)
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mice or rats [19, 33], a day point when we observe that 
Col1a1+ PSCs are infrequent. That Col1a1+ PSCs may 
originate in the meninges and “move” into the perivascu-
lar space along arterioles and venules that penetrate the 
surface of the brain is consistent with the anatomy of the 
interface between the meninges and perivascular gaps 
called Virchow-Robin spaces (VRs) (Fig. 6A). VRs start at 
the point where a vessel in the pial layer of the meninges 
penetrates the brain surface and runs the length of pen-
etrating arterioles and venules [4]. In this way, VRs are 
largely continuous with the pial space. VRs may play an 
important role in interstitial flow, essentially helping to 
flush cellular debris, notably β-amyloid, out of the brain 
parenchyma [4, 38]. Possibly, VRs also represent an entry 
point for Col1a1+ meningeal cells from the pial layer of 
the meninges to enter the perivascular space. Our model 
is supported by electron microscopy analysis at both the 
meninges-VRs interface and arterioles within the brain 
where researchers have characterized pial fibroblasts 
entering VRs from the meninges [25, 32] and surround-
ing the vSMC layer of arterioles within the brain paren-
chyma [54].
PSCs that contribute to fibrotic scar formation were, 
for a long time, mistaken for meningeal fibroblasts that 
move into the injured CNS after injury-induced damage 
to the pial basement membrane [1, 51]. This was based, 
in part, on the observation that fibrotic cells in the scar 
were continuous with the meningeal space and expressed 
markers also expressed by meningeal fibroblasts [5]. 
Recent lineage tracing using the GLAST-CreErt and 
Col1a1-GFP lines, however, provide compelling evi-
dence that the fibrotic scar is generated by the resident 
PSC population and not meningeal fibroblasts moving 
into injured tissue [13, 48]. Our data provides new insight 
into why PSCs were erroneously identified as meningeal 
fibroblasts in that we show that PSCs express many of 
the same proteins. It is not clear, however, how or why 
cells might move from the meninges into the perivascu-
lar space of the early postnatal brain. It is possible that 
PSCs in the brain are an artifact of blood vessel devel-
opment during postnatal brain growth. Conceivable, 
pial meningeal fibroblasts are “pulled” into the develop-
ing brain along the large blood vessel tracts and brain 
growth around the vessels displaces PSCs deeper into 
brain structures. It cannot be an entirely passive process, 
however, since we observe that PSCs are proliferating in 
the early postnatal brain (data not shown). Also, Col1a1+ 
PSCs increase expression of certain markers like Raldh1, 
Raldh2, PDGFrα, and CRABP1 over time, suggesting that 
they undergo differentiation in the perivascular space and 
thus are likely a unique cell type from meningeal fibro-
blasts. Our analysis also indicates there is heterogeneity 
in PSCs within the injury site. We observe that only some 
PSCs in the lesion express Raldh1, Raldh2 and CRABP2, 
suggesting they may be more than one type of PSC. More 
studies are needed to define different subtypes of PSCs, 
their origin and function following brain injury.
The meninges are a source of RA for the develop-
ing and adult brain [26, 45] and we find that Col1a1+ 
PSCs express RA biosynthesis and signaling proteins. 
The dramatic expansion of this population, along with 
infiltration of large numbers of Raldh1-expressing mac-
rophages, following brain ischemia creates a concen-
trated pool of RA synthesizing cells within the lesion 
core. Consistent with this, we show that the presence of 
numerous Raldh-expressing cells correlates with a sig-
nificant increase in RA levels in the stroke hemisphere 
at 7 days post-injury. Significantly, when we use the RA 
signaling reporter, RARE-hsp68-LacZ, we show that 
elevated RA synthesis in the core stimulates RA sign-
aling activity in peri-infarct neurons and astrocytes at 
the same time-point. Our data are consistent with tran-
scription profiling of stroke tissue from rat showing 
Fig. 6 Model of PSC development in the post-natal brain and as a 
source of RA following stroke injury. Potential model of how during 
post-natal brain development Col1a1+ cells (putative PSCs) could 
‘move’ from the meningeal space to the perivascular space around 
large diameter blood vessels via Virchow-Robin Spaces (A). Following 
injury Raldh1+ macrophages/microglia and Raldh1/2+ PSCs within 
the ischemic core produce RA capable of activating RA signaling in 
adjacent peri-infarct astrocytes and neurons (B)
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up-regulation of both Raldh2 and CRABP2 in the 
ischemic hemisphere following injury [15]. Following 
spinal cord injury, increased numbers of Raldh2+ cells 
have been reported, along with elevated RA levels and 
signaling [21, 34, 35]. Considering our characterization 
of Raldh2+ cells in stroke injury, Raldh2+ cells in spi-
nal cord lesions described in these studies are very likely 
PSCs. If that is the case, RA synthesis by PSCs may be a 
common function of this injury-activated cell type fol-
lowing CNS injury.
Our identification of cells in the stroke lesion as a 
source of RA has implications for how bioactive ligands 
emanating from the lesion may play a previously 
unknown role in recovery from ischemic injury. Reports 
in the stroke literature regarding the effect of exogenous 
treatment of RA on focal ischemic injury generally con-
clude that RA is beneficial though different stroke models 
and exogenous RA treatment regimens were used. Exog-
enous RA results in a smaller lesion [6, 24], improved 
blood brain barrier integrity [24], reduced neuroinflam-
matory response accompanied by decreased hippocam-
pal cell death and improved behavioral recovery [22], and 
increased neurogenesis and improved neurobehavioral 
outcomes when coupled with environmental enrichment 
[42]. Possibly, endogenous RA synthesis mediated by 
PSCs and macrophages that we describe here has similar 
effects as reported for exogenous RA in the post-stroke 
environment. In this way, injury-induced production of 
RA in the lesion may create a dynamic signaling envi-
ronment for neurons and glia that could aid in recovery 
following brain ischemia. Future studies aimed at phar-
macologically inhibiting endogenous RA synthesis fol-
lowing stroke injury will provide important insight into 
the function of endogenous, lesion-derived RA in stroke 
recovery.
Work thus far on PSCs has focused on their pro-fibrotic 
function with the idea that therapies to inhibit PSC popu-
lation expansion would block fibrotic scar deposition and 
promote neural recovery. Inhibition or reduction of col-
lagen IV and CSPGs (chondroitin sulfate proteoglycans) 
can attenuate CNS fibrosis [44, 52], however the extent 
to which that promotes neuronal repair in vivo following 
injury is not clear [18]. Blocking the TGFβ pathway fol-
lowing CNS injury decreases ECM deposition and size of 
the fibrotic scar, but there is not a corresponding recov-
ery of axonal growth [23, 27–29, 37]. These results sug-
gest that blocking fibrotic scar formation is not sufficient 
for full, functional recovery of the tissue. Importantly, 
though PSCs contribute to fibrotic scar formation, our 
work outlined here suggests they may also have a protec-
tive function via secretion of bioactive ligands that pro-
mote recovery, namely RA. In this way, PSCs may play an 
unexpected, dual role in regeneration and fibrosis within 
the injured brain tissue and therapeutic strategies aimed 
purely at preventing PSC expansion are potentially not 
ideal.
Conclusions
Our research supports a dual role for post-injury, acti-
vated PSCs where in addition to contributing to fibro-
sis, PSCs secrete signaling molecule RA. In this way, 
activated PSCs are potentially capable of influencing of 
recovery following brain injury.
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